June 23, 2016
Wellesley, Mass., June 23, 2016 – During the past decade, the chronic kidney disease (CKD) rate has risen by more than 25% in the U.S. BCC Research reveals in its new report that the predominant growth drivers of the renal disease market include an aging population, increasing awareness of both acute and chronic kidney disease, and rising number of individuals with insurance due to the Affordable Care Act.
The kidneys have numerous life-sustaining functions, such as cleansing blood by filtering waste and excess fluid, maintaining the balance of salt and other minerals, and regulating blood pressure. When the kidneys are damaged and remain untreated, they eventually lose their vital function, which is fatal. Kidney failure can be developed acutely (acute kidney injury, or AKI) or over time (CKD). Three categories of treatment are most prevalent: prescription medications, dialysis (hemodialysis, peritoneal dialysis and continuous renal replacement therapy) and surgical intervention, which are often used in combination to treat a single case of renal failure.
The overall U.S. market in kidney treatment should reach $39.4 billion and $45.6 billion in 2016 and 2021, respectively, reflecting a five-year compound annual growth rate (CAGR) of 3%. As a segment, AKI treatment should grow the fastest among treatment markets, demonstrating a five-year CAGR of 5.1%. Chronic kidney disease treatment, the largest treatment market, should grow to $42.8 billion by 2021 on a five-year CAGR of 2.8%.
The population of end-stage renal disease (ESRD) is just 1% of the U.S. Medicare population but accounts for 7% of the Medicare budget. Kidney failure is the ninth-leading cause of death in the U.S. According to the National Kidney Foundation, Medicare spends, on average, $106,000 for a transplant (including the first year of monitoring) and $24,600 a year for the immunosuppressive drugs, compared to about $86,300 for a year of dialysis.
Hemodialysis (HD) and peritoneal dialysis (PD) are the two existing modalities for the renal replacement treatment of the ESRD population. While HD has dominated the market for decades, PD has become the largest-growing segment in recent years. The market for dialysis therapies is valued at $15.4 billion in 2016 and growing at a CAGR of 2.7%.
Peritoneal dialysis is estimated to generate $1.8 billion in 2016, which totaled 11.4% of the dialysis market. The five-year CAGR of treatment market is expected at 14.2%, bringing the market to about $3.5 billion by 2021. The segment is dominated by continuous cycling peritoneal dialysis (CCPD), with 50,100 patients in 2016, in which 85% are covered by Medicare.
“According to the ESRD Network Organization Program 2012 Annual Report, CCPD was the fastest-growing dialysis mode from 2010 to 2013, with a CAGR of 16% and expanded from 20,600 to 32,000 patients in three years,” says BCC Research analyst Cheng-Yuk Lee. “BCC Research applied the same CAGR and calculated 105,000 patients will choose CCPD treatment by 2021 and generate $3.3 billion to the dialysis market, comprising 17.4% of the market.”
Renal Disease Treatments: Products and Therapies (HLC073B) analyzes kidney failure treatment products and services, including pharmaceuticals, hemodialysis and peritoneal dialysis products and services, and surgical procedures used to keep the end-stage kidney patient alive. Analyses of global market drivers and trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.
Renal Disease Treatments: Products and Therapies( HLC073B )
Publish Date: Jun 2016
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.